Why is Brawn Biotech falling/rising?

As of 11-Aug, Brawn Biotech Ltd's stock is currently priced at 17.50, reflecting a decrease of 0.4, or 2.23%. The stock has been underperforming significantly, having fallen for the last four consecutive days, resulting in a 12.06% decline over the past week. It is trading below all key moving averages, indicating a bearish trend. Additionally, the stock's delivery volume has plummeted by 98.15% compared to its five-day average, suggesting a lack of investor interest. The company is facing severe operational challenges, with net sales declining at an annual rate of 22.97% and operating profit plummeting by 209.72% over the last five years. The negative EBITDA and weak ability to service debt further exacerbate the stock's poor performance.
In the broader market context, Brawn Biotech's recent performance contrasts sharply with the Sensex, which has only declined by 0.51% over the past week. While the stock has generated a return of -4.68% over the past year, the Sensex has seen a modest gain of 1.13%. This stark difference highlights the stock's significant underperformance relative to the market. The company's weak long-term fundamentals and operational losses contribute to its risk profile, making it a strong sell in the current environment.